Background: Prior research has established a correlation between CD10 and the biological aggressiveness exhibited by many human malignancies.
Objective: This research aimed to assess CD10 expression in invasive breast carcinoma and its correlation with clinic-pathological characteristics.
Methodology: This descriptive cross-sectional study included 60 cases diagnosed as invasive breast carcinoma, aged between 30 and 70 years. They were submitted to the histopathology lab at Al-Zahraa University Hospital. An immunohistochemical method was used to show expression of CD10 in the cases of invasive breast carcinoma.
Results: In 78.4% of the cases, the expression of CD10 was detected in the cytoplasm of stromal fusiform cells (46.7% as weak expression and 31.7% as strong expression). The incidence of stromal CD10 positivity was considerably higher in tumors that had metastases to lymph nodes (p = 0.038), a notable quality with increased tumor differentiation (p ≤0.05), and tumor size (p = 0.017). Additionally, CD10 correlated with estrogen receptor (ER) expression (p ≤ 0.05), progesterone receptor (PR) expression (p ≤ 0.05) and Ki-67 expression (p ≤ 0.05).
Conclusion: These outcomes revealed that the stromal CD10 expression may serve as an independent prognostic indicator in the advancement and spread of breast cancer and may participate in the progression of novel therapies for breast carcinoma.